NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT ID: NCT06081244
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
348 participants
INTERVENTIONAL
2024-10-10
2029-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Sacituzumab Govitecan In TNBC
NCT04230109
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the neoadjuvant setting, it has been shown that the prognosis of patients with TNBC is strongly dependent on their response to NACT: Patients achieving pathological complete response (pCR), or a near pCR (an excellent response after NACT (residual cancer burden (RCB) score 0-1), in some studies do have an excellent prognosis that is not significantly different from that observed in other breast cancer subtypes. However, patients with a less responsive disease (i.e., with RCB Score 2-3) suffer from a significantly worse prognosis compared to non-TNBC.
Chemotherapy in TNBC The optimal chemotherapy regimen for patients with TNBC remains to be identified. Standard anthracycline-taxane (A/T)-based NACT combinations render pCR rates between 25-50%. However, the survival impact of anthracyclines remains controversial due to conflicting results of different randomized trials. Adding carboplatin (carbo) to A/T-containing poly-NACT or use of dose-intensified poly-NACT significantly increases pCR-rates up to 49-60% in mostly stage II-III disease with conflicting survival results and higher toxicity. Hence, use of pragmatic taxane-carboplatin anthracycline-free combinations appears as an effective treatment option in TNBC instead of further treatment escalation. This probably is independent of the germline BRCA (gBRCA) status, due to its general chemo-predictive effect. Unfortunately, no prospective phase-III-data are available so far. However, indirect comparison between trials renders similar pCR rates in taxane-carboplatin based vs. A/T+/-carbo-based regimens in early TNBC.
In the ADAPT-TN neoadjuvant trial, the taxane-carbo arm (12-week nab-paclitaxel (nab-pac)+carbo) was well tolerable (only 10% SAE-rate), highly effective (pCR, ypT0/is/ypN0, of 46%) and superior to the gemcitabine (gem)-arm (nab-pac+gem, pCR of 29%). In this study, omission of further chemotherapy was allowed in patients with pCR after 12 weeks of therapy and was not associated with decreased survival after 3 years \[5\] and longer follow up.
Although a standard chemotherapy as well as optimal therapy duration are still to be defined, several studies are showing a comparable efficacy for longer vs. shorter adjuvant treatments in TNBC \[3\], as well as a similar efficacy regarding pCR in HR-negative (in contrast to HR-positive) early breast cancer (eBC) \[26\]. Moreover 6 vs. 4 cycles of the same chemotherapy (AC or pac weekly) yielded a similar survival outcome in eBC despite of HR-status. No such comparison regarding treatment duration is available for modern antibody-drug conjugates like sacituzumab govitecan (SG).
Therefore, an examination of shorter (12 weeks vs. 18 weeks) regimen as neoadjuvant treatment appears to be a very promising strategy at least in patients with lower risk disease or in elderly patients, who do not qualify for polychemotherapy treatments.
In the Keynote-522 trial combination of carboplatin/taxane-anthracycline NACT with the anti-PD1-antibody pembrolizumab (PEM) has been shown to be associated with a significantly higher pCR and clinically meaningful better EFS and a trend to better OS. Noteworthy only patients with more advanced stages IIa-III TNBC were included into the Keynote-522 trial. Although this effect was independent of clinically assessed nodal status, there is still some uncertainty on the optimal treatment in patients with clinical stage I.
In the metastatic setting, SG as a Trop-2-antibody-drug-conjugate has been shown to be highly efficacious in severely pre-treated patients (all with A/T pre-treated tumours, most of them carboplatin and 1/3 also anti-PD1 pre-treated) compared to chemotherapy of investigator´s choice. Treatment with SG was associated with significant longer median PFS (5.5 vs. 1.7 months) and longer median OS (12.1 vs. 6.7 months). Objective response was dramatically higher in the SG group vs. treatment by physician´s choice group (34.9 vs. 4.7%), in particular in the 2nd-3rd-line therapy (40% vs. 4%). Moreover, Tropics-02 trial has shown higher efficacy of SG vs. chemotherapy of investigator´s choice in patients with HR-positive/HER2-negative metastatic breast cancer.
In the neoadjuvant setting, recently presented results from the NeoSTAR trial show a promising pCR-rate of 30% and RCB 0-1-rate of 36% in TNBC patients with mostly stage II-III-disease (about 80%) after only 4 cycles of SG.
The following clinical questions are of highest medical need
1. Can 12-18 weeks neoadjuvant treatment with SG alone or in combination with PEM be associated with comparable pCR-rates (but more favourable safety profile) as shown for polychemotherapy in TNBC patients at lower relapse risk in historical controls?
2. Can SG-based therapy, as the most promising agent in patients with chemo-resistant disease, be associated with a such better prognosis (measured by 3-year-iDFS) compared to historical controls, which would make a randomized phase III-trial obsolete?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neoadjuvant treatment: 12 weeks (4 cycles) SG i.v.
* Cohort 1a: In case of (near) cCR: end of treatment, followed by surgery
* Cohort 1b: In case of cPR after 12 weeks: further 6 weeks (2 cycles) SG i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment
* In case of pCR: no further systemic treatment
* In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12
Sacituzumab govitecan
10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Neoadjuvant treatment: 12 weeks (4 cycles) SG+PEM i.v.
* Cohort 2a: In case of (near) cCR: end of treatment, followed by surgery
* Cohort 2b: In case of cPR after 12 weeks: 6 weeks (2 cycles) SG+PEM i.v., followed by surgery (use of core biopsy is allowed per investigator´s decision, if further NACT is planned) pCR dependent post-neoadjuvant treatment
* In case of pCR: no further systemic treatment
* In case of non-pCR: chemotherapy according to investigators decision, e.g., AC/EC q3w x 4, PAC/Carbo q1w x 12
Sacituzumab govitecan
10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Pembrolizumab
200 mg every 3 weeks (q3w)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab govitecan
10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
Pembrolizumab
200 mg every 3 weeks (q3w)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All patients, independent from gender
3. ≥18 years at diagnosis
4. Histologically confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes.
5. Clinical stage I: cT1a-c, cN0 (clinical stage II only, if patient does not qualify for neoadjuvant polychemotherapy+PEM, e.g., elderly population, per investigator´s decision)
6. No clinical evidence for distant metastasis (M0)
7. Tumour block available for central pathology review
8. Performance Status ECOG ≤ 1 or KI ≥ 80%
9. Negative pregnancy test (urine or serum) within 7 days prior to registration in premenopausal patients
10. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
11. The patient must be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up
12. Laboratory requirements:
* Leucocytes ≥3.5 109/L,
* Neutrophils \> 1.5 109/L,
* Platelets ≥100 109/L,
* Haemoglobin ≥10 g/dL,
* AP \< 5.0 ULN,
* AST ≤2.5 x ULN,
* ALT ≤2.5 x ULN,
* Total bilirubin ≤1 x ULN,
* Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN
13. Clinical assessments:
• LVEF within normal limits of each institution, measured by echocardiography and normal ECG (within 42 days prior to treatment)
14. The following age-specific requirements apply:
* Women aged \<50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site.
* Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments.
15. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
16. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of screening and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
17. Female patients must not donate, or retrieve for their own use, ova from the time of randomisation and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study.
18. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period.
Exclusion Criteria
2. Prior malignancy with a disease-free survival of \< 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri
3. Any history of invasive breast cancer
4. Previous or concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor
5. Concurrent treatment with other experimental drugs
6. Participation in another interventional clinical trial with or without any investigational not marketed drug within 30 days prior to study entry
7. Concurrent pregnancy; patients of childbearing potential or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment
8. Breast feeding woman
9. Reasons indicating risk of poor compliance
10. Patients not able to consent
11. Known polyneuropathy ≥ grade 2
12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, autoimmune disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease
13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
14. History of pneumonitis
15. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to randomisation if required by local regulations or ethics committee (EC).
16. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
* Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
* Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
17. Patients who test positive for HIV antibody.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
West German Study Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Schmid, Prof Dr PHD
Role: PRINCIPAL_INVESTIGATOR
Westdeutsche Studiengruppe GmbH
Nadia Harbeck, Prof Dr
Role: PRINCIPAL_INVESTIGATOR
Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital
Oleg Gluz, PD Dr
Role: PRINCIPAL_INVESTIGATOR
Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach
Sherko Kuemmel, Prof Dr
Role: PRINCIPAL_INVESTIGATOR
Breast Centre, Kliniken Essen Mitte
Monika Graeser, PD Dr..
Role: PRINCIPAL_INVESTIGATOR
Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stadtklinik Baden-Baden / Brustzentrum
Baden-Baden, Baden-Wurttemberg, Germany
Kliniken Böblingen
Böblingen, Baden-Wurttemberg, Germany
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Baden-Wurttemberg, Germany
SLK Kliniken Heilbronn, Frauenklinik
Heilbronn, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
GRN Klinik Weinheim
Weinheim, Baden-Württembergs, Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Bavaria, Germany
Universitätsklinikum Augsburg A.ö.R.
Augsburg, Bavaria, Germany
Rotkreuzklinikum München
München, Bavaria, Germany
DBZ Onkologie GmbH
Berlin, Brandenburg, Germany
Klinikum Ernst von Bergmann gGmbH
Potsdam, Brandenburg, Germany
Klinikum Bremerhaven Reinkenheide gGmbH
Bremerhaven, City state Bremen, Germany
AGAPLESION Markus Krankenhaus
Frankfurt am Main, Hesse, Germany
MVZ II der Niels Stensen Kliniken
Georgsmarienhütte, Lower Saxony, Germany
Gynäkologische Gemeinschaftspraxis-Ärztehaus am Bahnhofsplatz
Hildesheim, Lower Saxony, Germany
Ev. Krankenhaus Berlin-Spandau
Berlin, North Rhine-Westphalia, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, North Rhine-Westphalia, Germany
St. Elisabeth-Krankenhaus Köln-Hohenlind
Cologne, North Rhine-Westphalia, Germany
Kliniken der Stadt Köln, Krankenhaus Holweide
Cologne, North Rhine-Westphalia, Germany
MVZ Medical Center Düsseldorf - GynOnco
Düsseldorf, North Rhine-Westphalia, Germany
St. - Antonius - Hospital
Eschweiler, North Rhine-Westphalia, Germany
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany
Kliniken Essen-Mitte
Essen, North Rhine-Westphalia, Germany
ev. Klinikum Gelsenkirchen - Klinik für Senelogie
Gelsenkirchen, North Rhine-Westphalia, Germany
St. Barbara Klinik Hamm GmbH
Hamm, North Rhine-Westphalia, Germany
Klinikum Leverkusen gGmbH
Leverkusen, North Rhine-Westphalia, Germany
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein
Mönchengladbach, North Rhine-Westphalia, Germany
MVZ MediaVita, St. Franziskus-Hospital Münster
Münster, North Rhine-Westphalia, Germany
MKS St.Paulus GmbH (ehem.Marienkrankenhaus)
Schwerte, North Rhine-Westphalia, Germany
Praxisnetzwerk Hämatologie und Onkologie, Troisdorf
Troisdorf, North Rhine-Westphalia, Germany
Marien Hospital Witten
Witten, North Rhine-Westphalia, Germany
Helios Universitätsklinikum Wuppertal Barmen
Wuppertal, North Rhine-Westphalia, Germany
Klinikum Mutterhaus-Trier
Trier, Rhineland-Palatinate, Germany
Caritasklinikum Saarbrücken
Saarbrücken, Saarland, Germany
Johanniter GmbH Johanniter Krankenhaus Stendal
Stendal, Sachsen-Anhalts, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany
Charité Campus Mitte Universitätsklinikum Berlin
Berlin, , Germany
Hämatologisch/Onkologische Schwerpunktpraxis Bremen
Bremen, , Germany
Mammazentrum Hamburg am Krankenhaus Jerusalem
Hamburg, , Germany
Klinikum der Universität München
München, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Martina Koch
Role: primary
Katharina Maier
Role: backup
Alexandra Vieweger
Role: primary
Marion Ruhs
Role: backup
Sabine Souchon
Role: primary
Manuela Rees
Role: backup
Yvonne Löffler
Role: primary
Bettina Walter-Thorwart
Role: backup
Evelyn Ziel
Role: primary
Emine Tan
Role: backup
Snjezana Stein
Role: primary
Antje Beyer
Role: backup
Sabine Holzinger
Role: primary
Nina Wittmann
Role: backup
Andrea Gerecke
Role: primary
Sonja Dannecker
Role: backup
Angret Wetzel
Role: primary
Katja Gauger
Role: backup
Bettina Schinke
Role: primary
Ina Lehmann
Role: backup
Madeleine Modrow
Role: primary
Aynur Koccu-Yüzlek
Role: backup
Nicole Weimer
Role: primary
Miriam Kischkel
Role: backup
Andrea Meyer-Kühn
Role: primary
Christoph Busch
Role: backup
Annette Romanski
Role: primary
Ute Moritz
Role: backup
Birgit Reunig- Bruns
Role: primary
Stefanie Horstmann
Role: backup
Sigrun Wolfsturm
Role: primary
Britta Wenzel
Role: backup
Fatima Kourisna
Role: primary
Alexandra Karachristos
Role: backup
Chehrzad Alipour
Role: primary
Juliane Lubitz
Role: backup
Gabi Ziemons
Role: primary
Franziska Wilhelm
Role: backup
Clarissa Judith Piotrowsky
Role: primary
Svenja Krüger
Role: backup
Sandra Riefers
Role: primary
Tanja Voelker
Role: backup
Simone Herholz
Role: primary
Nobubele Mlangeni
Role: backup
Anke Föert
Role: primary
Gabriele Kerkmann
Role: backup
Katja Pöggel-Krämer
Role: primary
Birsel Diyen
Role: backup
Carolin Sydlik
Role: primary
Mona Schwark
Role: backup
Sarah Damerau
Role: primary
Maria Walter
Role: backup
Johanna Westkämper
Role: primary
Kristin Backhaus
Role: backup
Petra Bois
Role: primary
Sylvia Gawor-Becker
Role: backup
Anika Schmidt
Role: primary
Baerbel Buchwald
Role: backup
Karina Weinhardt
Role: primary
Manuela Smiljanic
Role: backup
Bahareh Valadkhani
Role: primary
Eva Junk
Role: backup
Ulrike Schilling
Role: primary
Tina Kroneis
Role: backup
Beate Müller
Role: primary
Stefanie Stiller
Role: backup
Samira Michel
Role: primary
Andrea Bendig, Dr.rer.nat.
Role: backup
Stefanie Kreuzer
Role: primary
Heike Munzinger
Role: primary
Inga von Ahsen, Dr. rer.nat.
Role: backup
Silke Kassner
Role: primary
Kathleen Bever
Role: backup
Beate Rank
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WSG-AM13 (ADAPT-TN-III)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.